Investigational pharmacological agents for the treatment of ARDS
K Aribindi, M Lim, S Lakshminrusimha… - Expert Opinion on …, 2024 - Taylor & Francis
K Aribindi, M Lim, S Lakshminrusimha, T Albertson
Expert Opinion on Investigational Drugs, 2024•Taylor & FrancisABSTRACT Introduction Acute Respiratory Distress Syndrome (ARDS) is a heterogeneous
form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that
results in diffuse lung inflammation with a high mortality rate. While research in COVID
related ARDS has resulted in several pharmacotherapeutic agents that have undergone
successful investigation, non-COVID ARDS studies have not resulted in many widely
accepted pharmacotherapeutic agents despite exhaustive research. Areas covered The aim …
form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that
results in diffuse lung inflammation with a high mortality rate. While research in COVID
related ARDS has resulted in several pharmacotherapeutic agents that have undergone
successful investigation, non-COVID ARDS studies have not resulted in many widely
accepted pharmacotherapeutic agents despite exhaustive research. Areas covered The aim …
Introduction
Acute Respiratory Distress Syndrome (ARDS) is a heterogeneous form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that results in diffuse lung inflammation with a high mortality rate. While research in COVID related ARDS has resulted in several pharmacotherapeutic agents that have undergone successful investigation, non-COVID ARDS studies have not resulted in many widely accepted pharmacotherapeutic agents despite exhaustive research.
Areas covered
The aim of this review is to discuss adjuvant pharmacotherapies targeting non-COVID Acute Lung Injury (ALI)/ARDS and novel therapeutics in COVID associated ALI/ARDS. In ARDS, variable data may support selective use of neuromuscular blocking agents, corticosteroids and neutrophil elastase inhibitors, but are not yet universally used. COVID-ALI/ARDS has data supporting the use of IL-6 monoclonal antibodies, corticosteroids, and JAK inhibitor therapy.
Expert opinion
Although ALI/ARDS modifying pharmacological agents have been identified in COVID-related disease, the data in non-COVID ALI/ARDS has been less compelling. The increased use of more specific molecular phenotyping based on physiologic parameters and biomarkers, will ensure equipoise between groups, and will likely allow more precision in confirming pharmacological agent efficacy in future studies.
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果